Patents Assigned to Bioneer A/S
-
Patent number: 9937295Abstract: A syringe (1) for mixing and ejecting an active pharmaceutical ingredient is disclosed. The syringe (1) comprises a syringe body (2) defining a first lumen (8), a first plunger (4) arranged movably in said first lumen (8), said first plunger (4) being hollow, thereby defining a second lumen (9) being separated from the first lumen (8), and a second plunger (5) arranged movably in said second lumen (9). A liquid diluent is contained in one of the first lumen (8) and the second lumen (9), and an active pharmaceutical ingredient is contained in the other of the first lumen (8) and the second lumen (9). The second plunger (5) is movable in such a manner that the active pharmaceutical ingredient and the liquid diluent are brought together, e.g.Type: GrantFiled: February 2, 2012Date of Patent: April 10, 2018Assignee: BIONEER A/SInventor: Daniel Bar-Shalom
-
Patent number: 9795745Abstract: A syringe for mixing and ejecting an active pharmaceutical ingredient is disclosed. The syringe is designed in such a manner that it is ensured that substantially all of the mixed drug is ejected, and in such a manner that an active pharmaceutical ingredient can be lyophilized directly into the syringe. The syringe comprises a syringe body, a first plunger arranged movably inside the syringe body and a second plunger arranged movably inside the first plunger. In one aspect the second plunger comprises a first plunger part and a second plunger part, and the first and second plunger parts are adapted to cooperate to collapse the cavity of the first plunger. In a second aspect the cavity of the first plunger has a first diameter at a distal end and a second diameter at a proximal end, the first diameter being smaller than the second diameter.Type: GrantFiled: June 25, 2013Date of Patent: October 24, 2017Assignee: Bioneer A/SInventors: Daniel Bar-Shalom, Lasse Johansson
-
Publication number: 20140236121Abstract: A syringe (1) for mixing and ejecting an active pharmaceutical ingredient is disclosed. The syringe (1) comprises a syringe body (2) defining a first lumen (8), a first plunger (4) arranged movably in said first lumen (8), said first plunger (4) being hollow, thereby defining a second lumen (9) being separated from the first lumen (8), and a second plunger (5) arranged movably in said second lumen (9). A liquid diluent is contained in one of the first lumen (8) and the second lumen (9), and an active pharmaceutical ingredient is contained in the other of the first lumen (8) and the second lumen (9). The second plunger (5) is movable in such a manner that the active pharmaceutical ingredient and the liquid diluent are brought together, e.g.Type: ApplicationFiled: February 2, 2012Publication date: August 21, 2014Applicant: BIONEER A/SInventor: Daniel Bar-Shalom
-
Publication number: 20110142905Abstract: The present invention relates to a pharmaceutical composition for controlled delivery of at least one active ingredient into an aqueous phase, said pharmaceutical composition comprising: a tablet, preferably obtainable by compression, said tablet comprising said at least one active ingredient and optionally excipients; and a coating, applied on said tablet, said coating covering at least part of said tablet to impede the release of said at least one active ingredient from at least part of the surface of said tablet, said coating being applied in a manner allowing the release of said at least one active ingredient from said tablet after contacting said pharmaceutical composition with said aqueous phase, establishing one or more degradation surfaces of said tablet; wherein the first derivative of the area of each degradation surface with respect to time is larger than or equal to zero.Type: ApplicationFiled: August 14, 2009Publication date: June 16, 2011Applicant: BIONEER A/SInventors: Daniel Bar-Shalom, Kaisa Naelapää
-
Publication number: 20100266555Abstract: The present invention relates to the use of specified micro RNAs as markers of the functional state of a dendritic cell. In one aspect the invention relates to a method for producing a quality-controlled therapeutic composition comprising dendritic cells. In another aspect the invention relates to a method of in vitro screening of immunomodulatory compounds.Type: ApplicationFiled: November 14, 2008Publication date: October 21, 2010Applicants: DANDRIT BIOTECH A/S, BIONEER A/SInventors: Simon Skjøde Jensen, Kim Holmstrøm, Ayako Wakatsuki Pedersen, Mai-Britt Zocca
-
Publication number: 20080103055Abstract: The present invention relates to a novel polypeptide chain forming a particular 3 dimensional fold characterized by a ?-sandwich. By altering the amino acid sequence in specific regions of the polypeptide of the invention novel binding characteristics are developed. Methods for the generation of a polypeptide according to the invention and uses of polypeptides of the invention are also described.Type: ApplicationFiled: January 16, 2007Publication date: May 1, 2008Applicant: Bioneer A/SInventor: Peter Kristensen
-
Patent number: 7358067Abstract: The invention provides a fed-batch or continuous process for producing heterologous peptides, polypeptides or proteins in lactic acid bacteria, comprising the steps of (i) constructing a recombinant lactic acid bacterium comprising a nucleotide sequence coding for the heterologous peptide, polypeptide or protein, and appropriate regulatory nucleotide sequences such as regulatable promoters and signal peptides to control the expression of the coding sequence and the secretion of gene product, (ii) cultivating the recombinant bacterium under or continuous cultivation conditions to express the gene, and (iii) harvesting the recombinant bacterium or the gene product. Preferably, the cultivation medium is a chemically defined or synthetic medium optionally supplemented with yeast extract.Type: GrantFiled: October 19, 2001Date of Patent: April 15, 2008Assignee: Bioneer A/SInventors: Astrid Vrang, Søren Michael Madsen, Lars Bredmose, Peter Ravn, Jose Arnau, Mads Gronvald Johnsen, Anne Cathrine Steenberg, Hans Israelsen
-
Patent number: 7186815Abstract: A method of identifying nucleotide sequences coding for signal peptides in lactic acid bacteria, using a DNA molecule comprising a transposon including a promoterless reporter gene from which DNA molecule a region between the LR and the reporter gene is deleted and the DNA molecule comprises a DNA sequence coding for a secretion reporter molecule. By deleting the region between the LR and the reporter gene, stop codons in-frame with the secretion reporter molecule is removed which upon transposition permits translational fusions from upstream the LR.Type: GrantFiled: May 8, 2003Date of Patent: March 6, 2007Assignee: Bioneer A/SInventors: Peter Ravn, Soeren Michael Madsen, Astrid Vrang, Hans Israelsen, Mads Groenvold Johnsen, Lars Bredmose, José Arnau
-
Patent number: 7052898Abstract: A novel L-arabinose isomerase active enzyme and its corresponding gene, derived from a thermophilic source are provided. The enzyme is suitable for the production of D-tagatose, a useful low-calorie sweetener. The enzyme may be obtained from a Thermoanaerobacter species such as Thermoanaerobacter mathranii.Type: GrantFiled: July 15, 2002Date of Patent: May 30, 2006Assignee: Bioneer A/SInventors: Ole C. Hansen, Flemming Jørgensen, Peter Stougaard, Hans Bertelsen, Karen Bøttcher, Hans Jørgen Singel Christensen, Kristian Eriknauer